6.3 C
New York
Saturday, March 25, 2023

Medical Marijuana, Inc. subsidiary of HempMeds® Mexico participates in research to find promising therapeutic benefits of CBD in the treatment of Parkinson’s disease

- Advertisement -

SAN DIEGO, CA, Oct. 12, 2022 (GLOBE NEWSWIRE) — via NewMediaWireMedical marijuana, Inc. (OTC: MJNA) (the “Company”), the first publicly traded cannabis company in the United States that launched the first cannabis-derived products, brands, and supply chain, today announced that its HempMeds® Mexico subsidiary has teamed up with experts from the Merit University of Puebla, Mexico, and the University of Barcelona. Independent in Spain to conduct a new study to prove the benefits of CBD in the treatment of Parkinson’s disease.

The goal of the research protocol, which was carried out by professionals in neuropharmacology, neurochemistry, and neuroscience, was to show how the interaction of CBD with specific neuronal receptors, such as GPR55, can have positive effects on health in the central nervous system.

“In our paradigm, we examined the effect of CBD administered to rats that were in a state of Parkinson’s. Administration of CBD clearly improved motor performance during the administration of the experiment,” said Daniel Limon and Dr. Felipe Patricio of the Neuropharmacology Laboratory of the meritorious University of Puebla. The result was published. Study at Frontiers in Pharmacology and can be found here here.

To ensure the most reliable, scientifically valid and trustworthy results, HempMeds® provided its pioneer RSHO-X 5000 to aid in the implementation of the study.

Named one of the best CBD producers by CNBCMedical Marijuana Inc.’s flagship product. , Real scientific cannabis The oil has been used in many other successful clinical studies across Mexico and Brazil to understand its safety and effectiveness. Medical Marijuana, Inc. is the leader in advancing the availability of CBD products in international markets, and is the first company ever to receive historical import authorizations for CBD products from the governments of Brazil, Mexico, Argentina, and Paraguay.

“Our commitment is to provide free access to non-psychoactive cannabis and its benefits,” said Raul Elizalde, CEO of HempMeds. “We are pleased to fulfill this commitment with our contribution to this study and are very pleased with the results.”

Forward-looking Disclaimer:

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, and is subject to the safe harbor laws established by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and are subject to risks and uncertainties. These forward-looking statements, by definition, involve risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of Medical Marijuana, Inc. to differ. substantially more than those mentioned here.

Disclosure from the Food and Drug Administration (FDA):

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, cure, or prevent any disease.

Legal disclosure:

Medical Marijuana, Inc. does not sell or distribute any products that violate the US Controlled Substances Act.


Are you looking for marijuana business guides and books about  cannabis? Then you should not miss our online bookstore with hundreds of books about cannabis, CBD, THC and more!

Grow guide for marijuana beginners.
- Advertisement -THC University

Related Articles


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Stay Connected

- Advertisement -

Latest Articles